Cargando…
Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study
BACKGROUND: Monitoring vaccine effectiveness (VE) remains a priority for epidemiological research throughout the COVID-19 pandemic. VE against infection declines with the emergence of new SARS-CoV-2 variants of concern (VOC), but VE against the severe disease remains high. Therefore, we aimed to est...
Autores principales: | Barchuk, Anton, Bulina, Anna, Cherkashin, Mikhail, Berezina, Natalia, Rakova, Tatyana, Kuplevatskaya, Darya, Skougarevskiy, Dmitriy, Okhotin, Artemiy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549449/ https://www.ncbi.nlm.nih.gov/pubmed/36217139 http://dx.doi.org/10.1186/s12931-022-02206-3 |
Ejemplares similares
-
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study
por: Barchuk, Anton, et al.
Publicado: (2022) -
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia
por: Barchuk, Anton, et al.
Publicado: (2022) -
Antimicrobial Activity of the Serum before and after Vaccination with EpiVacCorona
por: Arzumanyan, V. G., et al.
Publicado: (2022) -
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
por: Kozlovskaya, Liubov I., et al.
Publicado: (2021) -
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
por: Gordeychuk, Ilya V., et al.
Publicado: (2023)